Alzamend Neuro, Inc. (ALZN) Cash Flow Statement
Where ALZN’s cash came from and went, FY2026
April 30, 2026 · U.S. dollars- Cash from operations
- −$8.1M
- Capital expenditures
- $0
- Free cash flow
- −$8.1M
- Returned to shareholders
- —
- Change in cash
- −$3.2M cash at year-end $710,689
Cash from operations
−$8.1M
Shares issued
+$4.8M
Change in cash
−$3.2M
Drawn to scale: where the cash came from and how it was used. Hover for values.
ALZN operating cash flow, capex and free cash flow
Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)
ALZN cash flow trends, FY2017–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$1.4MFY2017 | −$8.1MFY2026 | — | |
| Capital expenditures | $0FY2017 | $0FY2026 | — | |
| Free cash flow | −$1.4MFY2017 | −$8.1MFY2026 | — | |
| Stock-based compensation | $114,409FY2017 | $707,527FY2026 | +22.4%/yr | |
| Share buybacks (net) | $0FY2021 | $0FY2023 | — |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
ALZN cash flow by activity
OperatingInvestingFinancingChange in cash
ALZN net income vs operating cash flow
Net incomeOperating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
ALZN cash flow statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$8.8M | −$4.5M | −$9.9M | −$14.9M | −$12.4M | −$5.0M | −$4.4M | −$4.9M | −$931,663 | −$1.6M |
| Depreciation & amortization | $110,740 | $50,740 | $50,740 | $23,066 | $3,549 | $124,046 | $3,549 | $3,549 | — | — |
| Stock-based compensation | $707,527 | $325,108 | $955,633 | $3.6M | $4.4M | $2.0M | $1.8M | $396,170 | $218,417 | $114,409 |
| Change in working capital | −$113,698 | −$2.4M | $670,666 | $2.3M | $1.3M | −$152,451 | −$299,347 | $1.2M | −$1.3M | −$49,679 |
| Other non-cash items | $0 | $9,286 | $714 | $0 | $8,770 | $330,586 | $558,728 | $2.2M | $8,792 | $88,474 |
| Cash from operating activities | −$8.1M | −$6.6M | −$8.3M | −$8.9M | −$6.6M | −$2.7M | −$2.3M | −$1.0M | −$2.1M | −$1.4M |
| Investing activities | ||||||||||
| Capital expenditures | $0 | −$300,000 | −$147,243 | $0 | −$106,458 | −$106,458 | −$106,458 | −$106,458 | $0 | $0 |
| Investments (net) | — | −$300,000 | −$147,243 | −$147,243 | −$106,458 | $100,915 | $105,000 | $234,085 | — | — |
| Acquisitions & other investing | — | $300,000 | $147,243 | — | $106,458 | $106,458 | $106,458 | $106,458 | −$400,000 | −$400,000 |
| Cash from investing activities | — | −$300,000 | −$147,243 | — | −$106,458 | $100,915 | $105,000 | $234,085 | −$400,000 | −$400,000 |
| Financing activities | ||||||||||
| Share repurchases & issuance (net) | — | — | — | $200 | $6.0M | $2.1M | — | — | — | — |
| Net borrowing (repayment) | — | $0 | $300,000 | $0 | −$58,667 | $2.3M | −$16,666 | $72,697 | −$623,511 | $578,029 |
| Shares issued | $4.8M | $10.4M | $3.4M | $4.0M | $18.9M | $2.1M | $2.3M | $236,023 | $0 | $0 |
| Other financing | $0 | $600 | $0 | −$4.0M | −$6.0M | −$2.0M | $16,800 | $0 | $3.6M | $842,500 |
| Cash from financing activities | $4.8M | $10.4M | $3.7M | $200 | $18.9M | $4.5M | $2.3M | $308,720 | $3.0M | $1.4M |
| Summary | ||||||||||
| Net change in cash | −$3.2M | $3.6M | −$4.8M | −$8.9M | $12.1M | $1.8M | $47,679 | −$502,395 | $540,025 | $3,835 |
| Cash at end of period | $710,689 | $3.9M | $376,048 | $5.1M | $14.1M | $1.9M | $90,285 | $42,606 | $545,000 | $4,976 |
| Free cash flow | −$8.1M | −$6.9M | −$8.4M | −$8.9M | −$6.7M | −$2.7M | −$2.3M | −$1.0M | −$2.1M | −$1.4M |
| Jul '26 | Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | Oct '24 | Jul '24 | Apr '24 | Jan '24 | Oct '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$3.0M | −$2.9M | −$2.2M | −$1.0M | −$2.7M | −$1.1M | −$985,783 | −$1.4M | −$974,411 | −$851,529 | −$2.7M | −$2.9M |
| Depreciation & amortization | $27,685 | $27,685 | $27,685 | $27,685 | $27,685 | $12,685 | $12,685 | $12,685 | $12,685 | $12,685 | $12,685 | $12,685 |
| Stock-based compensation | $77,199 | $623,811 | $9,300 | $31,514 | $42,902 | $81,277 | $81,277 | $81,277 | $81,277 | $81,277 | $186,640 | $318,336 |
| Change in working capital | $1.8M | −$578,842 | −$714,128 | −$229,880 | $269,311 | $356,778 | −$531,817 | −$2.1M | −$184,579 | −$669,854 | $431,431 | $1.1M |
| Other non-cash items | −$2 | $1 | $1.1M | $0 | $0 | $0 | $0 | $0 | $9,286 | $714 | $1 | $0 |
| Cash from operating activities | −$1.1M | −$2.8M | −$1.7M | −$1.2M | −$2.4M | −$688,705 | −$1.4M | −$3.4M | −$1.1M | −$1.4M | −$2.0M | −$1.5M |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | −$210,000 | $0 | −$90,000 | −$90,000 | −$147,243 | $0 | $0 |
| Investments (net) | — | — | — | — | $0 | −$210,000 | $0 | $0 | −$90,000 | $0 | $0 | $0 |
| Acquisitions & other investing | — | — | — | — | — | $210,000 | — | — | $90,000 | $294,486 | — | — |
| Cash from investing activities | — | — | — | — | — | −$210,000 | — | — | −$90,000 | $147,243 | — | — |
| Financing activities | ||||||||||||
| Dividends paid | — | — | — | — | — | — | −$87,379 | — | — | — | — | — |
| Shares issued | $8.0M | $794,844 | $0 | $0 | $4.0M | $1.5M | $688,700 | $6.3M | $2.0M | $1.2M | $2.1M | $18,087 |
| Other financing | $0 | $0 | $0 | $0 | $0 | $600 | $87,379 | $0 | $0 | $300,000 | $0 | $0 |
| Cash from financing activities | $8.0M | $794,844 | $0 | $0 | $4.0M | $1.5M | $688,700 | $6.3M | $2.0M | $1.5M | $2.1M | $18,087 |
| Summary | ||||||||||||
| Net change in cash | $6.9M | −$2.0M | −$1.7M | −$1.2M | $1.7M | $590,523 | −$734,938 | $2.9M | $817,902 | $93,181 | $82,788 | −$1.5M |
| Cash at end of period | $7.6M | $710,689 | $2.7M | $4.4M | $5.6M | $3.9M | $3.4M | $4.1M | $1.2M | $376,048 | $282,867 | $200,079 |
| Free cash flow | −$1.1M | −$2.8M | −$1.7M | −$1.2M | −$2.4M | −$898,705 | −$1.4M | −$3.4M | −$1.1M | −$1.4M | −$2.0M | −$1.5M |
| Free cash flow margin | — | — | — | — | — | — | — | — | — | −1,874.5% | — | — |
| Capex / revenue | — | — | — | — | — | — | — | — | — | 193.5% | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
ALZN cash generation
In fiscal 2026 (ended April 30, 2026), Alzamend Neuro generated -$8.1 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$8.1 million. Cash and equivalents fell by $3.2 million over the year.
Related: ALZN income statement, ALZN balance sheet. See the ALZN stock overview for the latest quote and news.
ALZN cash flow FAQ
What is Alzamend Neuro's free cash flow?
Alzamend Neuro's free cash flow was -$8.1 million in fiscal 2026: -$8.1 million of operating cash flow minus $0 of capital expenditures It was -$6.9 million a year earlier..
How much cash does Alzamend Neuro generate from operations?
Alzamend Neuro generated -$8.1 million of cash from operating activities in fiscal 2026.